Drug Discovery

For MTX-E1, Montara Therapeutics is pairing the approved medicine everolimus with a second molecule intended to keep its activity out of peripheral tissues. The aim is to preserve the drug’s neurological benefit while reducing systemic effects that limit treatment. A successful combination could

A dual-action strategy utilizing small interfering RNA and small activating RNA provides a sophisticated framework for correcting the molecular imbalances found in complex human tumors. This innovative methodology represents a fundamental shift in modern oncology, moving away from universal,

The move toward fully automated organic synthesis is expected to significantly reduce the time required to bring life-saving treatments from the lab to clinical phases. While artificial intelligence has already revolutionized the digital design of complex molecules, the physical manifestation of

The reduction of intraretinal fluid in patients with Best vitelliform macular dystrophy provides an objective anatomical marker for the success of OPGx-BEST1 therapy. Modern ophthalmology is navigating a period of transformation as adeno-associated virus (AAV) gene therapies transition from

Industry analysts project that global peak annual sales for the pancreatic cancer treatment daraxonrasib could eventually reach eleven point five billion dollars. This staggering figure reflects the immense medical need for effective therapies targeting RAS-mutated cancers, which have long remained

The integration of NVIDIA computing into Danaher's diagnostic portfolio addresses the growing gap between rapid AI hypothesis generation and the slower pace of physical experimentation. As biological research scales in complexity, the traditional manual approach to laboratory work has become a